Agenus Inc. (NASDAQ:AGEN) – Research analysts at William Blair issued their FY2020 earnings estimates for Agenus in a report released on Monday. William Blair analyst J. Sonnier forecasts that the biotechnology company will earn ($1.17) per share for the year.

Other equities research analysts have also recently issued research reports about the stock. Maxim Group restated a “buy” rating and issued a $7.00 target price on shares of Agenus in a report on Sunday, April 23rd. HC Wainwright set a $5.00 target price on shares of Agenus and gave the stock a “hold” rating in a report on Saturday, May 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $6.33.

ILLEGAL ACTIVITY NOTICE: “Agenus Inc. (AGEN) Expected to Post FY2020 Earnings of ($1.17) Per Share” was reported by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at https://www.watchlistnews.com/agenus-inc-agen-expected-to-post-fy2020-earnings-of-1-17-per-share/1397647.html.

Agenus (NASDAQ AGEN) traded down 2.23% during midday trading on Tuesday, hitting $3.95. 421,530 shares of the company were exchanged. The stock has a 50 day moving average of $3.55 and a 200-day moving average of $3.87. Agenus has a 1-year low of $3.20 and a 1-year high of $7.49. The stock’s market capitalization is $391.52 million.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.14. The company had revenue of $26.96 million for the quarter, compared to analysts’ expectations of $5.22 million. Agenus had a negative net margin of 257.79% and a negative return on equity of 37,577.49%.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AGEN. Oracle Investment Management Inc. acquired a new position in Agenus during the first quarter valued at $6,444,000. State Street Corp increased its position in Agenus by 64.3% in the fourth quarter. State Street Corp now owns 3,502,274 shares of the biotechnology company’s stock valued at $14,430,000 after buying an additional 1,370,515 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Agenus by 3,447.2% in the first quarter. Goldman Sachs Group Inc. now owns 673,333 shares of the biotechnology company’s stock valued at $2,539,000 after buying an additional 654,351 shares during the last quarter. Marshall Wace LLP acquired a new position in Agenus during the fourth quarter valued at $2,044,000. Finally, MARSHALL WACE ASIA Ltd acquired a new position in Agenus during the first quarter valued at $1,561,000. Institutional investors and hedge funds own 42.61% of the company’s stock.

In other Agenus news, CEO Garo H. Armen purchased 100,000 shares of the firm’s stock in a transaction on Wednesday, April 12th. The shares were acquired at an average cost of $3.35 per share, for a total transaction of $335,000.00. Following the completion of the transaction, the chief executive officer now owns 1,389,021 shares of the company’s stock, valued at $4,653,220.35. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 7.90% of the stock is currently owned by company insiders.

About Agenus

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.